Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/103306
Title: | Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes | Authors: | Leibiger, Ingo B. Leibiger, Barbara Moede, Tilo Paschen, Meike Dicker, Andrea Abdulreda, Midhat H. Åvall, Karin Ali, Yusuf Daré, Elisabetta Köhler, Martin Ilegems, Erwin Graham, Mark Crooke, Rosanne M. Tay, Vanessa Shi Yun Refai, Essam Nilsson, Stefan K. Jacob, Stefan Selander, Lars Berggren, Per-Olof Juntti-Berggren, Lisa |
Keywords: | diabetes apoCIII insulin resistance pancreatic islets |
Issue Date: | 2015 | Source: | Åvall, K., Ali, Y., Leibiger, I. B., Leibiger, B., Moede, T., Paschen, M., et al. (2015). Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes. Proceedings of the National Academy of Sciences of the United States of America, 112(20), E2611-E2619. | Series/Report no.: | Proceedings of the National Academy of Sciences of the United States of America | Abstract: | Insulin resistance and β-cell failure are the major defects in type 2 diabetes mellitus. However, the molecular mechanisms linking these two defects remain unknown. Elevated levels of apolipoprotein CIII (apoCIII) are associated not only with insulin resistance but also with cardiovascular disorders and inflammation. We now demonstrate that local apoCIII production is connected to pancreatic islet insulin resistance and β-cell failure. An increase in islet apoCIII causes promotion of a local inflammatory milieu, increased mitochondrial metabolism, deranged regulation of β-cell cytoplasmic free Ca2+ concentration ([Ca2+]i) and apoptosis. Decreasing apoCIII in vivo results in improved glucose tolerance, and pancreatic apoCIII knockout islets transplanted into diabetic mice, with high systemic levels of the apolipoprotein, demonstrate a normal [Ca2+]i response pattern and no hallmarks of inflammation. Hence, under conditions of islet insulin resistance, locally produced apoCIII is an important diabetogenic factor involved in impairment of β-cell function and may thus constitute a novel target for the treatment of type 2 diabetes mellitus. | URI: | https://hdl.handle.net/10356/103306 http://hdl.handle.net/10220/25742 |
DOI: | 10.1073/pnas.1423849112 | Schools: | Lee Kong Chian School of Medicine (LKCMedicine) | Rights: | © 2015 The Author(s) (Published by National Academy of Sciences).This is the author created version of a work that has been peer reviewed and accepted for publication by Proceedings of the National Academy of Sciences of the United States of America, The Author(s) (Published by National Academy of Sciences). It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1073/pnas.1423849112]. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.pdf | 1.28 MB | Adobe PDF | ![]() View/Open |
SCOPUSTM
Citations
5
68
Updated on Mar 11, 2025
Web of ScienceTM
Citations
5
60
Updated on Oct 28, 2023
Page view(s) 20
724
Updated on Mar 15, 2025
Download(s) 50
192
Updated on Mar 15, 2025
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.